ValuEngine Upgrades Evofem Biosciences (EVFM) to “Sell”

Posted by Joseph Griffin on Apr 6th, 2018 // Comments off

Evofem Biosciences (NASDAQ:EVFM) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

EVFM has been the subject of several other research reports. BTIG Research reissued a “hold” rating on shares of Evofem Biosciences in a research note on Tuesday, March 20th. HC Wainwright assumed coverage on shares of Evofem Biosciences in a research note on Monday, March 19th. They issued a “buy” rating and a $15.00 price target for the company.

How to Become a New Pot Stock Millionaire

EVFM stock remained flat at $$6.20 during mid-day trading on Wednesday. 101 shares of the company’s stock were exchanged, compared to its average volume of 19,679. Evofem Biosciences has a 12 month low of $1.80 and a 12 month high of $15.78.

COPYRIGHT VIOLATION NOTICE: “ValuEngine Upgrades Evofem Biosciences (EVFM) to “Sell”” was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3335040/valuengine-upgrades-evofem-biosciences-evfm-to-sell.html.

Evofem Biosciences Company Profile

Evofem Biosciences, Inc develops therapeutic solutions to meet sexual and reproductive health needs of women. The company's product includes, Amphora contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections, and antimicrobial drug product to prevent the reoccurrence of bacterial vaginosis.

Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.